We recently submitted a letter to the Virginia Board of Pharmacy seeking clarification on its enforcement approach to compounded GLP-1 medications. Specifically, we’re concerned that the BoP’s actions appear inconsistent with both FDA guidance and Virginia law, particularly in cases where prescriptions document a patient-specific clinical difference. Our ask: Would the board be kind enough to clarify how it interprets key terms and standards so that pharmacies can be compliant and patients can still get the meds they need?